Trial | NCT00847899  Report issue

Title

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    ar-9281 ...

  • Study Participants

    150
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.
Study Started
Jan 31
2009
Primary Completion
Oct 31
2009
Study Completion
Nov 30
2009
Last Update
Nov 20
2009
Estimate

Drug AR9281

AR9281 taken in BID dosing regimen for 28 days

Drug AR9281

AR9281 taken in TID dosing regimen for 28 days

Drug Placebo

Placebo taken in BID dosing regimen for 28 days

Drug Placebo

Placebo taken in TID dosing regimen for 28 days

1 Active Comparator

AR9281

2 Active Comparator

AR9281

3 Placebo Comparator

Placebo

4 Placebo Comparator

Placebo

Criteria 

Inclusion Criteria:

mild to moderate hypertension
naive to antihypertensive medication or on two or less antihypertensive medications
impaired glucose tolerance
mild obesity

Exclusion Criteria:

Diagnosis of Type 1 or Type 2 diabetes
History of severe heart failure
AST, ALT levels more than twice the normal range
No Results Posted